bioMérieux Future Growth

Future criteria checks 3/6

bioMérieux is forecast to grow earnings and revenue by 13.5% and 7.4% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 12.8% in 3 years.

Key information

13.5%

Earnings growth rate

13.5%

EPS growth rate

Medical Equipment earnings growth	19.0%
Revenue growth rate	7.4%
Future return on equity	12.8%
Analyst coverage	Good
Last updated	17 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

WBAG:BIM - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,543	604	422	866	12
12/31/2025	4,217	533	377	804	13
12/31/2024	3,934	470	355	726	13
6/30/2024	3,807	411	156	495	N/A
3/31/2024	3,741	384	132	470	N/A
12/31/2023	3,675	358	107	445	N/A
9/30/2023	3,688	372	140	459	N/A
6/30/2023	3,701	386	172	472	N/A
3/31/2023	3,645	419	180	474	N/A
12/31/2022	3,589	452	188	475	N/A
9/30/2022	3,525	502	297	583	N/A
6/30/2022	3,460	552	406	690	N/A
3/31/2022	3,418	577	470	757	N/A
12/31/2021	3,376	601	535	825	N/A
9/30/2021	3,296	555	424	716	N/A
6/30/2021	3,216	509	314	608	N/A
3/31/2021	3,167	457	310	595	N/A
12/31/2020	3,118	404	305	583	N/A
9/30/2020	2,997	355	261	538	N/A
6/30/2020	2,876	305	217	493	N/A
3/31/2020	2,775	289	176	451	N/A
12/31/2019	2,675	273	135	408	N/A
9/30/2019	2,601	268	160	419	N/A
6/30/2019	2,527	263	185	431	N/A
3/31/2019	2,474	260	179	415	N/A
12/31/2018	2,421	257	173	400	N/A
9/30/2018	2,372	264	162	370	N/A
6/30/2018	2,323	271	150	340	N/A
3/31/2018	2,306	255	N/A	341	N/A
12/31/2017	2,288	238	N/A	341	N/A
9/30/2017	2,262	216	N/A	340	N/A
6/30/2017	2,237	195	N/A	339	N/A
3/31/2017	2,170	187	N/A	337	N/A
12/31/2016	2,103	179	N/A	336	N/A
9/30/2016	2,068	158	N/A	339	N/A
6/30/2016	2,032	137	N/A	342	N/A
3/31/2016	1,998	124	N/A	326	N/A
12/31/2015	1,965	111	N/A	310	N/A
9/30/2015	1,908	127	N/A	N/A	N/A
6/30/2015	1,851	144	N/A	301	N/A
3/31/2015	1,775	140	N/A	300	N/A
12/31/2014	1,698	135	N/A	298	N/A
9/30/2014	1,656	135	N/A	N/A	N/A
6/30/2014	1,614	135	N/A	246	N/A
3/31/2014	1,601	150	N/A	243	N/A
12/31/2013	1,588	164	N/A	241	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIM's forecast earnings growth (13.5% per year) is above the savings rate (1.2%).

Earnings vs Market: BIM's earnings (13.5% per year) are forecast to grow faster than the Austrian market (7% per year).

High Growth Earnings: BIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIM's revenue (7.4% per year) is forecast to grow faster than the Austrian market (-0.5% per year).

High Growth Revenue: BIM's revenue (7.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (12.8%).

bioMérieux Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

First half 2024 earnings released: EPS: €1.83 (vs €1.37 in 1H 2023)

bioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

New minor risk - Earnings quality

Dividend of €0.85 announced

Full year 2023 earnings released: EPS: €3.03 (vs €3.84 in FY 2022)

bioMérieux S.A., Annual General Meeting, May 23, 2024

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Upcoming dividend of €0.85 per share at 0.9% yield

Full year 2022 earnings released: EPS: €3.84 (vs €5.08 in FY 2021)

bioMérieux Introduces GENE-UP ENVIROPRO

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Now 21% undervalued

Now 22% undervalued

Upcoming dividend of €0.85 per share

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

Now 25% undervalued after recent price drop

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

New 90-day low: €111

bioMérieux S.A., Annual General Meeting, May 20, 2021

bioMérieux S.A. Announces the Expansion of the Ce Marking of Its Molecular Biology Argene® Sars-Cov-2 Diagnostic Test to Include Saliva Specimens

bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions with Data Science, Sequencing and Predictive Modeling

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies